Integral control of cardiovascular risk factors in type 2 diabetes in the Pallars Jussà and Sobirà regions (area of influence of the regional hospital of Pallars-Lleida);Control integral de los factores de riesgo cardiovascular en diabetes tipo 2 en dos comarcas rurales

Revista Clinica Espanola

Volumn 210, Issue 7, 2010, Pages 332-337

  Diez Porres L ^a   Riart Solans, M ^b   Foix Ona, M ^b   Morilla, L ^b   Mitjana Isarn, R ^b   Salvador Milian, E ^a   Escur Pujol, L ^b  

^a Hospital Comarcal del Pallars   (Spain)

^b ICS   (Spain)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Quality of life; Risk factors; Rural population

Indexed keywords

AGED; CARDIOVASCULAR DISEASES; COMPLICATION; CROSS-SECTIONAL STUDY; FEMALE; HEALTH; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SPAIN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RURAL HEALTH; SPAIN;

EID: 77956673848     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2009.12.012     Document Type: Article

References (18)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
2. Bayo J, Sola C, García F, Latórre PM, Vázquez JA. Prevalencia de la diabetes mellitus no dependiente de insulina en Lejona (Vizcaya). Med Clin (Barc). 1993;101:609-12.
3. Valdés S, Rojo-Martínez G, Soriguer F. Evolución de la prevalencia de la diabetes tipo 2 en población adulta española. Med Clin (Barc). 2007;129:352-5.
4. Banegas JR, Rodriguez-Artalejo F, Graciani A, Villar F, Herruzo R. Mortality attributable to cardiovascular risk factors in Spain. Eur J Clin Nutr. 2003;57(Suppl 1):S18-21.
5. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL, for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905-12.
6. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
7. Llisterri Caro JL, Rodraíguez Roca GC, Alonso Moreno FL, Santos Rodraíguez JA, Carrasco Carraso E, Aguirre Rodríguez JC, et al. en representacioan del Grupo de Trabajo de Hipertensiaon Arterial de la Sociedad Española de Medicina Rural y Generalista (Grupo HTA/SEMERGEN) y de los investigadores del estudio EVENTO. Control de la hipertension arterial y de otros factores de riesgo cardiovascular en poblaciaon de alto riesgo asistida en Atenciaón Primaria. Estudio EVENTO. SEMERGEN. 2005;31:53-60.
8. Peña Fernandez A, Suarez Fernandez C, Cuende Melero I, Muñoz Rodraíguez M, Garré Canovas J, Camafort Babkowski M, et al. Grupo estudio CIFARC (Grupo Riesgo Vascular SEMI). Control integral de los factores de riesgo en pacientes de alto y muy alto riesgo cardiovascular en España. Estudio CIFARC. Med Clin (Barc). 2005;124:44-9.
9. Benito López P, García Mayor R, Puig Domingo M, Mesa Manteca J, Pallardo Sánchez LF, Faure Nogueras E, et al. del grupo investigador MIDIA. Perfil de los pacientes con diabetes mellitus tipo 2 en la Atencion Primaria. Rev Clin Esp. 2004;204:18-24.
10. Álvarez-Sala LA, Suárez C, Mantilla T, Franch J, Ruilope LM, Banegas JR, et al. en nombre del grupo PREVENCAT. Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria. Med Clin (Barc). 2005;124:406-10.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-72.
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
13. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32(suppl. 1):S6-12.
14. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-43.
15. Martin Luján F, Costa Pinel B, Cabré Vila JJ, Basora Gallisà J, Piñol Moreso JL, Solà Alberich R. Grupo de Investigación SM/ITG (Reus-Tarragona). Síndrome metabaólico y enfermedad cardiovascular en población diabética asistida en Atención Primaria. Hipertensión. 2004;21:339-46.
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R, on behalf of Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16.
17. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. On behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.